Jessica Hopfield

Insider profile

Currently holds positions in Editas Medicine Inc and Insulet Corp

Performance

Overall performance
3.2

Performance over holding periods
4.2
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 62% 68% 82%
Transactions
10 80% Buy
34 71% Buy
47 69% Buy

Performance for realised trades
4.4
Average return 482%
Success rate 73%
Average holding period 220
Transactions 28

Positions

Position Company Period
Independent Director Editas Medicine Inc Feb. 14, 2018 -
Independent Director Insulet Corp Dec. 1, 2018 -
Lead Independent Director Insulet Corp Aug. 1, 2016 - Dec. 1, 2018
Independent Director Insulet Corp July 28, 2015 - Aug. 1, 2016

Jessica Hopfield's trades of Maravai LifeSciences Holdings Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
24.84
Quantity 40,827
Value US$3,246,156
Transaction date
Sale
Price
175.31
Quantity 34,715 +28.0%
Value US$3,392,562
Transaction date
Proposed sale
Price
317.54
Quantity 5,235
Value US$1,662,322
Transaction date
Sale
Price
225.26
Quantity 7,628 -22.1%
Value US$1,718,283
Transaction date
Proposed sale
Price
225.26
Quantity 7,628
Value US$1,718,283
Transaction date
Purchase
Price
5.64
Quantity 45,000 +198.2%
Value US$253,868
Transaction date
Purchase
Price
5.64
Quantity 45,000 +198.2%
Value US$253,868
Transaction date
Purchase
Price
6.28
Quantity 80,000 +827.1%
Value US$502,400
Transaction date
Purchase
Price
45.51
Quantity 5,800 +34.3%
Value US$263,970
Transaction date
Purchase
Price
23.94
Quantity 10,200 +152.2%
Value US$244,188
Transaction date
Purchase
Price
19.23
Quantity 12,800 +inf%
Value US$246,190
Transaction date
Purchase
Price
38.68
Quantity 2,580 +20.4%
Value US$99,783
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2025-12-19 2025-12-19 PrS Proposed sale
37,461
49.81
US$2,193,655
37,461 49.81 US$2,193,655
2025-05-19 2025-05-19 PrS Proposed sale
40,827
24.84
US$3,246,156
40,827 24.84 US$3,246,156
2025-05-14 2025-05-13 S Sale
34,715 +28.0%
175.31
US$3,392,562
34,715 +28.0% 175.31 US$3,392,562
2025-05-13 2025-05-13 PrS Proposed sale
5,235
317.54
US$1,662,322
5,235 317.54 US$1,662,322
2024-09-12 2024-09-11 S Sale
7,628 -22.1%
225.26
US$1,718,283
7,628 -22.1% 225.26 US$1,718,283
2024-09-11 2024-09-11 PrS Proposed sale
7,628
225.26
US$1,718,283
7,628 225.26 US$1,718,283
2024-05-14 2024-05-13 B Purchase
45,000 +198.2%
5.64
US$253,868
45,000 +198.2% 5.64 US$253,868
2024-05-14 2024-05-13 B Purchase
45,000 +198.2%
5.64
US$253,868
45,000 +198.2% 5.64 US$253,868
2022-03-11 2022-03-10 B Purchase
80,000 +827.1%
6.28
US$502,400
80,000 +827.1% 6.28 US$502,400
2021-03-05 2021-03-03 B Purchase
5,800 +34.3%
45.51
US$263,970
5,800 +34.3% 45.51 US$263,970
2020-11-25 2020-11-24 B Purchase
50,000 +421.9%
27.00
US$1,350,000
50,000 +421.9% 27.00 US$1,350,000
2019-03-07 2019-03-05 B Purchase
10,200 +152.2%
23.94
US$244,188
10,200 +152.2% 23.94 US$244,188
2019-03-06 2019-03-05 B Purchase
12,800 +inf%
19.23
US$246,190
12,800 +inf% 19.23 US$246,190
2017-05-12 2017-05-11 B Purchase
2,580 +20.4%
38.68
US$99,783
2,580 +20.4% 38.68 US$99,783